Recent studies have shown that HPD can occur in patients with advanced hepatocellular carcinoma treated with anti-PD-1 antibodies, suggesting that ICIs may even be harmful in this setting [566]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.